Back HIV Basic Science Inflammation

Inflammation & Immune Activation

Tenofovir and Valganciclovir Reduce Inflammation in People with HIV

The antiretroviral drug tenofovir and the anti-herpes drug valganciclovir may help reduce harmful immune activation and inflammatory activity in HIV positive people.

Read more:

Inflammation Linked to Higher Mortality Even for People with High CD4 Cell Counts

Inflammation was associated with an increased risk of death among HIV positive participants in the FRAM study, according to a report in the November 1, 2012, Journal of Acquired Immunodeficiency Syndromes. People with the highest levels of 2 inflammation biomarkers -- fibrinogen and CRP -- had more than 2.5-fold higher mortality than those with the lowest levels. Inflammation remained a predictor of mortality even among people with CD4 counts above 500 cells/mm3.

Read more:

Inflammation Biomarkers Linked to Increased Risk of Death in People with HIV

HIV positive people with elevated levels of C-reactive protein (CRP) and fibrinogen, 2 biomarkers associated with inflammation and blood clotting, had a significantly higher risk of death over 5 years, according to a report in the November 1, 2010 Journal of Acquired Immune Deficiency Syndromes. These findings suggest that inflammation remains an important risk factor for mortality even among individuals with relatively high CD4 cell counts, the researchers concluded.

Read more:

Can Statins Reduce Inflammation in People with HIV?

Statin medications such as atorvastatin (Lipitor), usually used to lower blood cholesterol, may also reduce immune activation in HIV positive people, according to a small study described in the March 15, 2011, Journal of Infectious Diseases. Reducing immune activation and inflammation may decrease the risk of chronic non-AIDS conditions such as cardiovascular disease, but a much larger study will be required to demonstrate clinical benefits.

Read more:

Early Antiretroviral Treatment Can Help Preserve B-Cell Immune Function

People with HIV have lower levels of antibody-producing B-cells than HIV negative individuals, but numbers rise significantly after initiation of effective antiretroviral therapy (ART), according to a study published in the September 13, 2010 advance online edition of Blood. What's more, people at an early stage of HIV infection had more fresh B-cells and achieved full recovery, while those with chronic infection had more immature or exhausted cells and did not reach normal levels, suggesting it may be beneficial to start ART sooner, while B-cell immune function is still relatively well preserved.

Read more: